Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Scientific Reports|July 24, 2025
Impact of the PD-1/PD-L1 inhibitor SCL-1 on MDA-MB231 tumor growth in a humanized MHC-double knockout NOG mouse modelTomoatsu Ikeya, Tadashi Ashizawa, Akari Kanematsu, et al.
Biomedical Research (Tokyo, Japan)|October 6, 2024
Identification of membrane proteins targeted by small-molecule compounds using nanomagnetic beadsYasufumi Kikuchi, Takayuki Ando, Tadashi Ashizawa, et al.
Biomedical Research (Tokyo, Japan)|December 17, 2019
Antitumor activity of the PD-1/PD-L1 binding inhibitor BMS-202 in the humanized MHC-double knockout NOG mouseTadashi Ashizawa, Akira Iizuka, Emiko Tanaka, et al.
Cancer Immunology, Immunotherapy : CII|June 19, 2012
Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assayYasuto Akiyama, Masaru Komiyama, Yoji Nakamura, et al.
Anticancer Research|September 26, 2025
Pancancer Landscape of Long Non-coding RNA Expression and Immune Status of the Tumor Microenvironment in Japanese Cancer PatientsTomoatsu Ikeya, Yasuto Akiyama, Haruo Miyata, et al.
International Journal of Oncology|May 14, 2014
Effect of the STAT3 inhibitor STX-0119 on the proliferation of a temozolomide-resistant glioblastoma cell lineTadashi Ashizawa, Yasuto Akiyama, Haruo Miyata, et al.
Cancer Science|December 11, 2014
Immunologically augmented skin flap as a novel dendritic cell vaccine against head and neck cancer in a rat modelKeita Inoue, Noriko Saegusa, Maho Omiya, et al.
Anticancer Research|July 20, 2021
Alternative Evaluation of an ELISPOT Assay Using Cytokine Activity as a Novel ParameterChie Maeda, Akira Iizuka, Haruo Miyata, et al.
Oncology Reports|May 21, 2014
YKL-40 downregulation is a key factor to overcome temozolomide resistance in a glioblastoma cell lineYasuto Akiyama, Tadashi Ashizawa, Masaru Komiyama, et al.
Cancer Genomics & Proteomics|December 30, 2016
Combination of a STAT3 Inhibitor and an mTOR Inhibitor Against a Temozolomide-resistant Glioblastoma Cell LineHaruo Miyata, Tadashi Ashizawa, Akira Iizuka, et al.
Pageof 5